SHORT TITLE: Clear Outcomes

RESEARCH PROTOCOL TITLE: A randomized, Double-Blind, Placebo-Controlled Study to Access the Effects of Bempedoic Acid (ETC-1002) on the Occurrence of Major Cardiovascular Events in Patients with, or at High Risk for Cardiovascular Disease who are Statin Intolerant

PRINCIPAL INVESTIGATOR: David Lewis, MD

RESEARCH SPONSOR: Esperion Therapeutics, Inc.

Clinical Trials.Gov Listing at:
https://clinicaltrials.gov/ct2/show/NCT02993406?term=bempedoic&rank=2

STUDY PURPOSE
The purpose of this study is to evaluate if taking Bempedoic Acid (the study drug) reduces the risk of cardiovascular events such as heart attack, stroke, heart pain or death in patients who are intolerant of statins.

STUDY PROCEDURES
The study will last between 3 and 5 years with study visits every 6 months after the first year. Phone call visits will be conducted in between clinic visits. There are more frequent visits the first year of the study. During the study visits vital signs (weight, blood pressure and pulse) will be taken, questionnaires completed, and study medication will be collected and re-dispensed. Some visits will include a physical exam by a study doctor.

ELIGIBILITY CRITERIA FOR SUBJECTS
1. Be willing to sign informed consent
2. Be 18 years of age or older
3. Be intolerant to statin medications
4. Be at risk of cardiovascular disease

SUBJECT PAYMENT
Participants will be compensated $50 (fifty) for each completed clinic study visit.

RESEARCH LOCATION AND CONTACT PERSON
Barbara Loomis, RN, BSN, CCRC
UnityPoint Health-Meriter-Heart & Vascular Institute
2601 West Beltline Hwy.
Suite 200
Madison, WI 53713

PHONE: 608-417-2168